What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T cell therapy
The Lymphoma Hub and Multiple Myeloma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale…